Do you guys think its going to launch as an Adamas product or a Forest product? I'm thinking Adamas in the US, Forest everywhere else. As someone personally affected by the disease, I really wish someone was working towards INNOVATIVE discoveries in alzheimers, rather than just slapping lego's together and calling it something new... IMHO- this drug is not innovative or helpful to patients at all. The advantage provided by once daily dosing doesn't justify the additional cost for the branded medication. Particularly since, in most instances the therapy is administered by a caregiver. Do you guys still have your sales conference in march?
